Previous 10 | Next 10 |
Data From All Four Patient Show Improvements Lineage Cell reported new data from the fourth cohort in its Phase 1/2a clinical trial for OpRegen. The data is from the fourth patient in the cohort that received the highest quantity of OpRegen cells. The results showed restoration of cellular str...
Four Patients With Dry Age-Related Macular Degeneration Observed to Have Areas of Geographic Atrophy Which Diminished or Remained Unchanged Relative to Baseline for a Period of at Least 12 Months All Four Patients Exhibited Improvements in Visual Acuity at 12 Months ...
Ongoing Clinical Trial Data Continue to Demonstrate a Single Administration of OpRegen Can Provide Anatomical and Functional Improvements in Patients with Dry Age-Related Macular Degeneration with Geographic Atrophy All Three Cases of Retinal Restoration Have Shown Evidence ...
Image source: The Motley Fool. Lineage Cell Therapeutics, Inc. (NYSEMKT: LCTX) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Lineage Cell Therapeutics, Inc. (LCTX) Q3 2021 Earnings Ca...
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2021 Earnings Conference Call November 10, 2021, 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Ioana Hone – Director of Investor Relations at Lineage Kevin Cook – Chief Financial Officer Gary Ho – S...
Lineage Cell Therapeutics (NYSE:LCTX): Q3 GAAP EPS of -$0.05 in-line. Revenue of $2.27M (+298.2% Y/Y) beats by $1.76M. Press Release Cash, cash equivalents, and marketable securities totaled $65.1 million as of September 30, 2021. For further details see: Lineage Cell Therapeutics EPS i...
OpRegen ® Continues to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Performance Testing Underway to Support New Delivery Device for OPC1 Clinical Trials Cash, Cash Equivalents, and Marketable Securities of $65.1 Million ...
OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2021 financial and operating results on Wednesday, November 10, ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 1/2a clinical study of its lead product candidate, OpRegen ...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...